Innovative Therapeutics in Oncology and Neuroscience
Key 2024 Priorities, Milestones and Catalysts
Commercial Execution
VYVGART ramp-up in gMG post-NRDL
Maintain ZE JULA leadership position in ovarian cancer
Continue to grow supplemental coverage support for
Optune
Clinical Data and Regulatory Actions
Potential China approvals
•
• SUL-DUR (ABC)
• SC efgartigimod (gMG)
Repotrectinib (ROS1 NSCLC)
Planned China submissions
• SC efgartigimod (CIDP)
Clinical Development
•
Bemarituzumab in two Ph3 trials
KarXT bridging confirmatory study in China
ZL-1102 (IL-17 HumabodyⓇ) moving into full global
Ph2 development
•
Adagrasib (2L+ NSCLC)
.
TIVDAK (2L+ CC)
⚫TTFields (2L+ NSCLC)
Key clinical data
TTFields in 1L NSCLC BM and 1L pancreatic cancer
•
•
Enroll patients in global Ph1 study for ZL-1310 (DLL3)
Adagrasib in 1L NSCLC and 2L+ NSCLC1
Abbreviations: National reimbursement drug list (NRDL), non-small cell lung cancer (NSCLC), brain metastases from NSCLC (NSCLC BM), acinetobacter baumannii-calcoaceticus complex (ABC), chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP), generalized myasthenia gravis (gMG), cervical cancer (CC).
15 Note: (1) Subject to satisfaction of customary closing conditions; anticipated closing by 1H 2024. The data readouts are referring to Phase 2 KRYSTAL-17 study for 1L NSCLC (TPS<50%) and Phase 3 KRYSTAL-12 study for 2L+ NSCLC.
zaiLabView entire presentation